BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17027656)

  • 21. Rituximab and chemotherapy in diffuse large B-cell lymphoma.
    Sonet A; Bosly A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):719-26. PubMed ID: 19496708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
    Olivieri A; Lucesole M; Capelli D; Gini G; Montanari M; Candela M; Troiani E; Scortechini I; Poloni A; Leoni P
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):627-36. PubMed ID: 16041313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?
    Dreyling M; Hiddemann W
    Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress in therapeutic strategy for malignant lymphoma].
    Ogura M
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):309-27. PubMed ID: 15791814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C
    Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials for malignant lymphoma in Japan.
    Tobinai K; Hotta T
    Jpn J Clin Oncol; 2004 Jul; 34(7):369-78. PubMed ID: 15342663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatment strategies for aggressive lymphoma.
    Younes A
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):10-3. PubMed ID: 15726533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
    Bosly A; Bron D; Van Hoof A; De Bock R; Berneman Z; Ferrant A; Kaufman L; Dauwe M; Verhoef G
    Ann Hematol; 2008 Apr; 87(4):277-83. PubMed ID: 17952688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.
    Zwick C; Gleissner B; Pfreundschuh M
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S43-9. PubMed ID: 18284715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM; Wang L; Shen Y; Xia ZG; Chen Y; Chen QS; Chen Y; Zeng XY; You JH; Qian Y; Shen ZX
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients.
    Guyot A; Ortonne N; Valeyrie-Allanore L; Bagot M
    Arch Dermatol; 2010 Jan; 146(1):89-91. PubMed ID: 20083704
    [No Abstract]   [Full Text] [Related]  

  • 33. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
    Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
    Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The standard treatments for patients with hematological malignancies in Japan].
    Ishizawa K
    Gan To Kagaku Ryoho; 2007 May; 34(5):709-12. PubMed ID: 17496442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Management of diffuse large B-cell lymphoma in the rituximab era].
    Kinoshita T
    Rinsho Ketsueki; 2009 Oct; 50(10):1342-50. PubMed ID: 19915341
    [No Abstract]   [Full Text] [Related]  

  • 36. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
    Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
    Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard treatment of advanced-stage diffuse large B-cell lymphoma.
    Coiffier B
    Semin Hematol; 2006 Oct; 43(4):213-20. PubMed ID: 17027655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
    Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
    Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
    [No Abstract]   [Full Text] [Related]  

  • 39. [Non-Hodgkin lymphoma].
    Ogawa M
    Gan To Kagaku Ryoho; 1996 Aug; 23(9):1143-8. PubMed ID: 8751801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.
    Oprea C; Cainap C; Azoulay R; Assaf E; Jabbour E; Koscielny S; Lapusan S; Vanel D; Bosq J; Ribrag V
    Br J Haematol; 2005 Nov; 131(4):468-71. PubMed ID: 16281936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.